NEW YORK (GenomeWeb) – Exosome Diagnostics has raised about $1.5 million in private financing toward a targeted financing of $2.2 million, it said in a regulatory document filed on Monday.
The raise is an extension of the Cambridge, Massachusetts-based molecular diagnostic firm's Series B round, which raised $27 million in March 2014, a spokesperson for the firm told GenomeWeb.
She did not disclose the name of the investors in the round but said that Exosome Dx is moving its lead tests toward commercialization with plans to launch a solid tumor panel liquid biopsy this year. Based on simple blood samples, the test will cover 26 genes and 1,000 associated mutations "in the most significant cancer pathways," including EGFR/MAPK and P13K, she said, adding it will initially be made available to pharmaceutical firms as a clinical development tool.
The company is also eyeing launches this year of plasma-based liquid biopsy tests for the EML4-ALK and EGFR T790M mutations in non-small cell lung cancer, and a urine-based liquid biopsy test for prostate cancer, the spokesperson said.